Genetics and metabolism of lipoprotein(a) and their clinical implications (Part 2)

Wiener Klinische Wochenschrift

Volumn 111, Issue 2, 1999, Pages 46-55

  Dieplinger, Hans ^b   Kronenberg, Florian ^a  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPROTEIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ATHEROSCLEROSIS; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFECT; GENETICS; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIPOPROTEIN METABOLISM; NEPHROTIC SYNDROME; NONHUMAN; PROTEINURIA; REVIEW; RISK FACTOR; TRANSGENIC ANIMAL;

ARTERIOSCLEROSIS; CEREBROVASCULAR DISORDERS; DIABETES MELLITUS; HUMANS; KIDNEY DISEASES; LIPOPROTEIN(A); MYOCARDIAL INFARCTION; RISK FACTORS;

EID: 0033613973     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. Kronenberg F, Steinmetz A, Kostner GM, Dieplinger H (1996) Lipoprotein(a) in health and disease. Crit Rev Clin Lab Sci 33: 495-543
2. Rath M, Niendorf A, Reblin T, Dietel M, Krebber HJ, Beisiegel U (1989) Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 9: 579-592
3. Jamieson DG, Usher DC, Rader DJ, Lavi E (1995) Apolipoprotein(a) deposition in atherosclerotic plaques of cerebral vessels. A potential role for endothelial cells in lesion formation. Am J Pathol 147: 1567-1574
4. Kostner GM, Avogaro P, Cazzolato G, Marth E. Bittolo-Bon G, Quinci GB (1981) Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis 38: 51-61
5. Sandkamp M, Funke H, Schulte H, Köhler E, Assmann G (1990) Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age. Clin Chem 36: 20-23
6. Armstrong VW, Cremer P, Eberle E, Manke A, Schulze F, Wieland H, Kreuzer H, Seidel D (1986) The association between serum Lp (a) concentrations and angiographically assessed coronary atherosclerosis - dependence on serum LDL-levels. Atherosclerosis 62: 249-257
7. Genest J Jr., Jenner JL, McNamara JR, Ordovas JM, Silberman SR, Wilson PWF, Schaefer EJ (1991) Prevalence of lipoprotein (a) [Lp(a)] excess in coronary artery disease. Am J Cardiol 67: 1039-1045
8. Sandholzer C, Saha N, Kark JD, Rees A, Jaross W, Dieplinger H, Hoppichler F, Boerwinkle E, Utermann G (1992) Apo(a) isoforms predict risk for coronary heart disease: a study in six populations. Arterioscler Thromb 12: 1214-1226
9. Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM, Williams RR (1997) Lipoprotein(a) interactions with lipid and nonlipid risk factors in early familial coronary artery disease. Arterioscler Thromb Vasc Biol 17: 2783-2792
10. Seed M, Hoppichler F, Reaveley D, McCarthy S, Thompson GR, Boerwinkle E, Utermann G (1990) Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med 322: 1494-1499
11. Mancini FP, Newland DL, Mooser V, Murata J, Marcovina S, Young SG, Hammer RE, Sanan DA, Hobbs HH (1995) Relative contributions of apolipoprotein(a) and apolipoprotein-B to the development of fatty lesions in the proximal aorta of mice. Arterioscler Thromb Vasc Biol 15: 1911-1916
12. Alaigh P, Hoffman CJ, Korlipara G, Neuroth A, Dervan JP, Lawson WE, Hultin MB (1998) Lipoprotein(a) level does not predict restenosis after percutaneous transluminal coronary angioplasty. Arterioscler Thromb Vasc Biol 18: 1281-1286
13. Gotoh T, Kuroda T, Yamasawa M, Nishinaga M, Mitsuhashi T, Seino Y, Nagoh N, Kayaba K, Yamada S, Matsuo H (1995) Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort Study). Am J Cardiol 76: 928-932
14. Stein JH, Rosenson RS (1997) Lipoprotein Lp(a) excess and coronary heart disease. Arch Intern Med 157: 1170-1176
15. Coleman MP, Key TJ, Wang DY, Hermon C, Fentiman IS, Allen DS, Jarvis M, Pike MC, Sanders TA (1992) A prospective study of obesity, lipids, apolipoproteins and ischaemic heart disease in women. Atherosclerosis 92: 177-185
16. Ridker PM, Hennekens CH, Stampfer MJ (1993) A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 270: 2195-2199
17. Alfthan G, Pekkanen J, Jauhiainen M, Pitkäniemi J, Karvonen M, Tuomilehto J, Salonen JT, Ehnholm C (1994) Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 106: 9-19
18. Barnathan ES (1993) Has lipoprotein 'little' (a) shrunk? JAMA 270: 2224-2225
19. Assmann G, Schulte H, Von Eckardstein A (1996) Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 77: 1179-1184
20. Bostom AG, Gagnon DR, Cupples LA, Wilson PWF, Jenner JL, Ordovas JM, Schaefer EJ, Castelli WP (1994) A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women: The Framingham Heart Study. Circulation 90: 1688-1695
21. Bostom AG, Cupples LA, Jenner JL, Ordovas JM, Seman LJ, Wilson PW, Schaefer EJ, Castelli WP (1996) Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA 276: 544-548
22. Klausen IC, Sjol A, Hansen PS, Gerdes LU, Moller L, Lemming L, Schroll M, Faergeman O (1997) Apolipoprotein(a) isoforms and coronary heart disease in men: a nested case-control study. Atherosclerosis 132: 77-84
23. Wild SH, Fortmann SP, Marcovina SM (1997) A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants [published erratum appears in Arterioscler Thromb Vasc Biol 1997 May;17(5):1010]. Arterioscler Thromb Vasc Biol 17: 239-245
24. Költringer P, Jürgens G (1985) A dominant role of lipoprotein(a) in the investigation and evaluation of parameters indicating the development of cervical atherosclerosis. Atherosclerosis 58: 187-198
25. Jovicic A, Ivanisevic V, Ivanovic I (1993) Lipoprotein(a) in patients with carotid atherosclerosis and ischemic cerebrovascular disorders. Atherosclerosis 98: 59-65
26. Ridker PM, Stampfer MJ, Hennekens CH (1995) Plasma concentration of lipoprotein(a) and the risk of future stroke. JAMA 273: 1269-1273
27. Kronenberg F, Kathrein H, König P, Neyer U, Sturm W, Lhotta K, Gröchenig E, Utermann G, Dieplinger H (1994) Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. Arterioscler Thromb 14: 1405-1411
28. Brown SA, Morrisett JD, Boerwinkle E, Hutchinson R, Patsch W (1993) The relation of lipoprotein[a] concentrations and apolipoprotein[a] phenotypes with asymptomatic atherosclerosis in subjects of the Atherosclerosis Risk in Communities (ARIC) study. Arterioscler Thromb 13: 1558-1566
29. Willeit J, Kiechl S, Santer P, Oberhollenzer F, Egger G, Jarosch E, Mair A (1995) Lipoprotein(a) and asymptomatic carotid artery disease. Evidence of a prominent role in the evolution of advanced carotid plaques: the Bruneck Study. Stroke 26: 1582-1587
30. Mölgaard J, Klausen IC, Lassvik C, Færgeman O, Gerdes LU, Olsson AG (1992) Significant association between low-molecular-weight apolipoprotein(a) isoforms and intermittent claudication. Arterioscler Thromb 12: 895-901
31. Lawn RM, Wade DP, Hammer RE, Chiesa G, Verstuyft JG, Rubin EM (1992) Atherogenesis in transgenic mice expressing human apolipoprotein(a). Nature 360: 670-672
32. Boonmark NW, Lou XJ, Yang ZJ, Schwartz K, Zhang JL, Rubin EM, Lawn RM (1997) Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice. J Clin Invest 100: 558-564
33. Lou XJ, Boonmark NW, Horrigan FT, Degen JL, Lawn RM (1998) Fibrinogen deficiency reduces vascular accumulation of apolipoprotein(a) and development of atherosclerosis in apolipoprotein(a) transgenic mice. Proc Natl Acad Sci U S A 95: 12591-12595
34. Linton MF, Farese RV, Jr., Chiesa G, Grass DS, Chin P, Hammer RE, Hobbs HH, Young SG (1993) Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a). J Clin Invest 92: 3029-3037
35. Callow MJ, Verstuyft J, Tangirala R, Palinski W, Rubin EM (1995) Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a). J Clin Invest 96: 1639-1646
36. Sanan DA, Newland DL, Tao R, Marcovina S, Wang J, Mooser V, Hammer RE, Hobbs HH (1998) Low density lipoprotein receptor-negative mice expressing human apolipoprotein B-100 develop complex atherosclerotic lesions on a chow diet: no accentuation by apolipoprotein(a). Proc Natl Acad Sci U S A 95: 4544-4549
37. Rouy D, Duverger N, Lin SD, Emmanuel F, Houdebine LM, Denefle P, Viglietta C, Gong E, Rubin EM, Hughes SD (1998) Apolipoprotein(a) yeast artificial chromosome transgenic rabbits. Lipoprotein(a) assembly with human and rabbit apolipoprotein B. J Biol Chem 273: 1247-1251
38. Faucher C, Doucet C, Baumelou A, Chapman J, Jacobs C, Thillet J (1993) Elevated lipoprotein (a) levels in primary nephrotic syndrome. Am J Kidney Dis 22: 808-813
39. Wanner C, Rader D, Bartens W, Krämer J, Brewer HB, Schollmeyer P, Wieland H (1993) Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome. Ann Intern Med 119: 263-269
40. Stenvinkel P, Berglund L, Heimbürger O, Pettersson E, Alvestrand A (1993) Lipoprotein(a) in nephrotic syndrome. Kidney Int 44: 1116-1123
41. Dieplinger H, Lackner C, Kronenberg F, Sandholzer Ch, Lhotta K, Hoppichler F, Graf H, König P (1993) Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). J Clin Invest 91: 397-401
42. De Sain-Van Der Velden MG, Reijngoud DJ, Kaysen GA, Gadellaa MM, Voorbij H, Stellaard F, Koomans HA, Rabelink TJ (1998) Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome. J Am Soc Nephrol 9: 1474-1481
43. Appel GB, Blum CB, Chien S, Kunis CL, Appel AS (1985) The hyperlipidemia of the nephrotic syndrome: relation to plasma albumin concentration, oncotic pressure and viscosity. N Engl J Med 312: 1544-1548
44. Parra HJ, Mezdour H, Cachera C, Dracon M, Tacquet A, Fruchard JC (1987) Lp(a) lipoprotein in patients with chronic renal failure treated by hemodialysis. Clin Chem 33: 721
45. Hirata K, Kikuchi S, Saku K, Jimi S, Zhang B, Naito S, Hamaguchi H, Arakawa K (1993) Apolipoprotein(a) phenotypes and serum lipoprotein(a) levels in maintenance hemodialysis patients with/without diabetes mellitus. Kidney Int 44: 1062-1070
46. Auguet T, Senti M, Rubies-Prat J, Pelegrí A, Pedro-Botet J, Nogués X, Romero R (1993) Serum lipoprotein(a) concentration in patients with chronic renal failure receiving hemodialysis: Influence of apolipoprotein(a) genetic polymorphism. Nephrol Dial Transplant 8: 1099-1103
47. Webb AT, Reaveley DA, O'Donnell M, O'Connor B, Seed M, Brown EA (1993) Lipoprotein (a) in patients on maintenance haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 8: 609-613
48. Zimmermann J, Herrlinger S, Pruy A, Wanner C (1997) Mechanism of high serum lipoprotein(a) in hemodialysis patients. J Am Soc Nephrol 8: 260A(Abstract)
49. Yang WS, Min WK, Park JS, Kim SB (1997) Effect of increasing serum albumin on serum lipoprotein(a) concentration in patients receiving CAPD. Am J Kidney Dis 30: 507-513
50. Black IW, Wilcken DEL (1992) Decreases in apolipoprotein(a) after renal transplantation: Implications for lipoprotein(a) metabolism. Clin Chem 38: 353-357
51. Kronenberg F, König P, Lhotta K, Königsrainer A, Sandholzer Ch, Utermann G, Dieplinger H (1993) Cyclosporin and serum lipids in renal transplant recipients. Lancet 341: 765
52. Azrolan N, Brown CD, Thomas L, Hayek T, Zhao ZH, Roberts KG, Scheiner C, Friedman EA (1994) Cyclosporin A has divergent effects on plasma LDL cholesterol (LDL-C) and lipoprotein(a) [Lp(a)] levels in renal transplant recipients: Evidence for renal involvement in the maintenance of LDL-C and the elevation of Lp(a) concentrations in hemodialysis patients. Arterioscler Thromb 14: 1393-1398
53. Kronenberg F, König P, Lhotta K, Öfner D, Sandholzer C, Margreiter R, Dosch E, Utermann G, Dieplinger H (1994) Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation. Arterioscler Thromb 14: 1399-1404
54. Webb AT, Reaveley DA, O'Donnell M, O'Connor B, Seed M, Brown EA (1993) Does cyclosporin increase lipoprotein(a) concentrations in renal transplant recipients? Lancet 341: 268-270
55. Hunt BJ, Parratt R, Rose M, Yacoub M (1994) Does cyclosporin affect lipoprotein(a) concentrations? Lancet 343: 119-120
56. Kerschdorfer L, König P, Neyer U, Bösmüller C, Lhotta K, Auinger M, Hohenegger M, Riegler P, Margreiter R, Utermann G, Dieplinger H, Kronenberg F (1999) Lp(a) plasma concentrations after renal transplantation: a prospective evaluation after four years of follow-up. Atherosclerosis (in press)
57. von Ahsen N, Helmhold M, Eisenhauer T, Armstrong VW, Oellerich M (1996) Decrease in lipoprotein(a) after renal transplantation is related to the glucocorticoid dose. Eur J Clin Invest 26: 668-675
58. Kandoussi AM, Hugue V, Cachera C, Hazzan M, Dracon M, Tacquet A, Noel C (1998) Apo(a) Phenotypes and Lp(a) concentrations in renal transplant patients. Nephron 80: 183-187
59. Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF (1992) Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 86: 475-482
60. Koch M, Kutkuhn B, Trenkwalder E, Bach D, Grabensee B, Dieplinger H, Kronenberg F (1997) Apolipoprolein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients. J Am Soc Nephrol 8: 1889-1898
61. Wanner C, Bartens W, Walz G, Nauck M, Schollmeyer P (1995) Protein loss and genetic polymorphism of apolipoprotein(a) modulate serum lipoprotein(a) in CAPD patients. Nephrol Dial Transplant 10: 75-81
62. Webb AT, Reaveley DA, O'Donnell M, O'Connor B, Seed M, Brown EA (1995) Lipids and lipoprotein(a) as risk factors for vascular disease in patients on renal replacement therapy. Nephrol Dial Transplant 10: 354-357
63. Appel G (1991) Lipid abnormalities in renal disease. Kidney Int 39: 169-183
64. Greiber S, Krämer-Guth A, Pavenstädt H, Gutenkunst M, Schollmeyer P, Wanner C (1996) Effects of lipoprotein(a) on mesangial cell proliferation and viability. Nephrol Dial Transplant 11: 778-785
65. Samuelsson O, Attman PO, Knight-Gibson C, Larsson R, Mulec H, Wedel H, Weiss L, Alaupovic P (1996) Plasma levels of lipoprotein(a) do not predict progression of human chronic renal failure. Nephrol Dial Transplant 11: 2237-2243
66. Haffner SM, Morales PA, Stern MP, Gruber MK (1992) Lp(a) concentrations in NIDDM. Diabetes 41: 1267-1272
67. Császár A, Dieplinger H, Sandholzer Ch, Karádi I, Juhász E, Drexel H, Halmos T, Romics L, Patsch JR, Utermann G (1993) Plasma lipoprotein(a) concentration and phenotypes in diabetes mellitus. Diabetologia 36: 47-51
68. Chang CJ, Kao JT, Wu TJ, Lu FH, Tai TY (1995) Serum lipids and lipoprotein(a) concentrations in Chinese NID-DM patients. Relation to metabolic control. Diabetes Care 18: 1191-1194
69. Klausen IC, Berg Schmidt E, Lervang HH, Gerdes LU, Ditzel J, Faergeman O (1992) Normal lipoprotein(a) concentrations and apolipoprotein(a) isoforms in patients with insulin-dependent diabetes mellitus. Eur J Clin Invest 22: 538-541
70. Couper JJ, Bates DJ, Cocciolone R, Magarey AM, Boulton TJC, Penfold JL, Ryall RG (1993) Association of lipoprotein(a) with puberty in IDDM. Diabetes Care 16: 869-873
71. Saber B, Stavljenic A, Jürgens G, Dumic M, Radica A (1993) Polymorphism of apolipoprotein E, lipoprotein(a), and other lipoproteins in children with type I diabetes. Clin Chem 39: 1427-1432
72. James RW, Boemi M, Sirolla C, Amadio L, Fumelli P, Pometta D (1995) Lipoprotein (a) and vascular disease in diabetic patients. Diabetologia 38: 711-714
73. Dubrey SW, Reaveley DR, Seed M, Lane DA, Ireland H, O'Donnell M, O'Connor B, Noble MI, Leslie RD (1994) Risk factors for cardiovascular disease in IDDM. A study of identical twins. Diabetes 43: 831-835
74. Austin MA, Sandholzer C, Selby JV, Newman B, Krauss RM, Utermann G (1992) Lipoprotein(a) in women twins: Heritability and relationship to apolipoprotein(a) phenotypes. Am J Hum Genet 51: 829-840
75. Purnell JQ, Marcovina SM, Hokanson JE, Kennedy H, Cleary PA, Steffes MW, Brunzell JD (1995) Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM. Results from follow-up in the Diabetes Control and Complications Trial. Diabetes 44: 1218-1226
76. Bruckert E, Davidoff P, Grimaldi A, Truffert J, Giral P, Doumith R, Thervet F, De Gennes JL (1990) Increased serum levels of lipoprotein(a) in diabetes mellitus and their reduction with glycemic control. JAMA 263: 35-36
77. Haffner SM, Tuttle KR, Rainwater DL (1991) Decrease of lipoprotein(a) with improved glycemic control in IDDM subjects. Diabetes Care 144: 302-307
78. Perez A, Carreras G, Caixas A, Castellvi A, Caballero A, Bonet R, Ordonez-Llanos J, de Leiva A (1998) Plasma lipoprotein(a) levels are not influenced by glycemic control in type 1 diabetes. Diabetes Care 21: 1517-1520
79. Jenkins AJ, Steele JS, Janus ED, Best JD (1991) Increased plasma apolipoprotein(a) levels in IDDM patients with microalbuminuria. Diabetes 40: 787-790
80. Kapelrud H, Bangstad H-J, Dahl-Jorgensen K, Berg K, Haussen KF (1991) Serum Lp(a) lipoprotein concentrations in insulin dependent diabetic patients with microalbuminuria. Br Med J 303: 675-678
81. Gall M-A, Rossing P, Hommel E, Voldsgaard AI, Andersen P. Nielsen FS, Dyerberg J, Parving H-H (1992) Apolipoprotein(a) in insulin-dependent diabetic patients with and without diabetic nephropathy. Scand J Clin Lab Invest 52: 513-521
82. Ruiz J, Thillet J, Huby T, James RW, Erlich D, Flandre P, Froguel P, Chapman J, Passa P (1994) Association of elevated lipoprotein(a) levels and coronary heart disease in NIDDM patients. Relationship with apolipoprotein(a) phenotypes. Diabetologia 37: 585-591
83. Hiraga T, Kobayashi T, Okubo M, Nakanishi K, Sugimoto T, Ohashi Y, Murase T (1995) Prospective study of lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease in patients with diabetes. Diabetes Care 18:241-244
84. Haffner SM, Moss SE, Klein BEK, Klein R (1992) Lack of association between lipoprotein (a) concentrations and coronary heart disease mortality in diabetes: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Metabolism 41: 194-197
85. Yamamoto M, Egusa G, Yamakido M (1997) Carotid atherosclerosis and serum lipoprotein(a) concentrations in patients with NIDDM. Diabetes Care 20: 829-831
86. Sechi LA, Kronenberg F, De Carli S, Falleti E, Zingaro L, Catena C, Utermann G, Bartoli E (1997) Association of serum lipoprotein(a) levels and apolipoprotein(a) size polymorphism with target-organ damage in arterial hypertension. JAMA 277: 1689-1695
87. Gregory WL, Game FL, Farrer M, Idle JR, Laker MF, James OFW (1994) Reduced serum lipoprotein(a) levels in patients with primary biliary cirrhosis. Atherosclerosis 105: 43-50
88. Marth E, Cazzolato G, Bon B, Avogaro P, Kostner GM (1982) Serum concentrations of Lp(a) and other lipoprotein parameters in heavy alcohol consumers. Ann Nutr Metab 26: 56-62
89. Matsuda J, Gotoh M, Gohchi K, Saitoh N, Tsukamoto M (1994) Serum lipoprotein(a) level is increased in patients with systemic lupus erythematosus irrespective of positivity of antiphospholipid antibodies. Thromb Res 73: 83-84
90. Rantapaa-Dahlqvist S, Wallberg-Jonsson S, Dahlen G (1991) Lipoprotein(a), lipids, and lipoproteins in patients with rheumatoid arthritis. Ann Rheum Dis 50: 366-368
91. Takahashi S, Yamamoto T, Moriwaki Y, Tsutsumi Z, Higashino K (1995) Increased concentrations of serum Lp(a) lipoprotein in patients with primary gout. Ann Rheum Dis 54: 90-93
92. Slunga L, Johnson O, Dahlen GH (1992) Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolaemia with simvastatin. Eur J Clin Pharmacol 43: 369-373
93. Carlson LA, Hamsten A, Asplund A (1989) Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidemic subjects treated with nicotinic acid. J Intern Med 226: 271-276
94. Albers JJ, Taggart HM, Appelbaum-Bowden D, Haffner F, Chesnut CH, Hazzard WR (1984) Reduction of LCAT, apo D and the Lp (a) lipoprotein with the anabolic steroid stanazolol. Biochim Biophys Acta 795: 293-296
95. Shewmon DA, Stock JL, Rosen CJ, Heiniluoma KM, Hogue MM, Morrison A, Doyle EM, Ukena T, Weale V, Baker S (1994) Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. Arterioscler Thromb 14: 1586-1593
96. Farish E, Barnes JF, Rolton HA, Spowart K, Fletcher CD, Hart DM (1994) Effects of tibolone on lipoprotein(a) and HDL subfractions. Maturitas 20: 215-219
97. Bosch T, Thiery J, Gurland HJ, Seidel D (1993) Long-term efficiency, biocompatibility, and clinical safety of combined simultaneous LDL-apheresis and haemodialysis in patients with hypercholesterolaemia and end-stage renal failure. Nephrol Dial Transplant 8: 1350-1358
98. Jansen M, Gabriel H, Banyai S, Pidlich J, Weidinger F, Horl WH, Derfler K (1996) Regression of coronary atherosclerosis and amelioration of renal function during LDL-immunoadsorption therapy in a renal transplant recipient. Wien Klin Wochenschr 108: 425-431
99. Frank S, Durovic S, Kostner K, Kostner GM (1995) Inhibitors for the in vitro assembly of Lp(a). Arterioscler Thromb Vasc Biol 15: 1774-1780
100. Berg AL, Arnadottir M, Kronenberg F, Lingenhel A, Hugosson T, Hegbrandt J, Nilsson-Ehle P (1998) ACTH-induced reduction of plasma lipoprotein(a) concentrations in healthy individuals and hemodialysis patients: relation to apo(a) size polymorphism. Metabolism (in press)
101. Berg AL, Nilsson-Ehle P (1996) ACTH lowers serum lipids in steroid-treated hyperlipemic patients with kidney disease. Kidney Int 50: 538-542
102. Arnadottir M, Berg AL, Dallongeville J, Fruchart JC, Nilsson-Ehle P (1997) Adrenocorticotrophic hormone lowers serum Lp(a) and LDL cholesterol concentrations in hemodialysis patients. Kidney Int 52: 1651-1655
103. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H (1990) Lipoprotein (a) and coronary heart disease: A prospective case-control study in a general population sample of middle aged men. Br Med J 301: 1248-1251
104. Sigurdsson G, Baldursdottir A, Sigvaldason H, Agnarsson U, Thorgeirsson G, Sigfusson N (1992) Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol 6916: 1251-1254
105. Cremer P, Nagel D, Labrot B, Mann H, Muche R, Elster H, Seidel D (1994) Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: Results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest 24: 444-453